Table 4. . Scenario analysis with generic pricing excluded: cost–effectiveness analysis results comparing apixaban switchers (to rivaroxaban) versus apixaban continuers.
| Apixaban continuers | Apixaban switchers (to rivaroxaban) | |
|---|---|---|
| Total costs | €20,146.80 | €28,723.91 |
| Total QALYs | 5.44 | 5.36 |
| Total LYs | 9.67 | 9.58 |
| Incremental costs and benefits vs apixaban continuers | ||
| Incremental costs | – | €8577.10 |
| Incremental QALYs | – | -0.079 |
| Incremental LYs | – | -0.086 |
| Cost–effectiveness vs apixaban continuers | ||
| Cost per QALY gained | – | Dominated |
| Cost per LY gained | – | Dominated |
LY: Life year; QALY: Quality-adjusted life year.